Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 224-924-0 | CAS number: 4553-89-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Repeated
dose toxicity: oral
The
NOAEL for Chocolate Brown HT (Disodium
4,4'-[[2,4-dihydroxy-5-(hydroxymethyl)-1,3-phenylene]bis(azo)]bisnaphthalene-1-sulphonate
) in male/ female Wistar rats was determined to be 500 mg/Kg/day.
Repeated
dose toxicity: inhalation
In
accordance with column 2 of Annex VIII of the REACH regulation, testing
by the inhalation route is appropriate if exposure of humans via
inhalation is likely taking into account the vapour pressure of the
substance. This chemical ha a very low vapour pressure of 1.48E-33
Pascal at 25°C and thus exposure by the inhlation route for this
chemical is unlikely.
Repeated
dose toxicity: dermal
The
chemical disodium
4,4'-[[2,4-dihydroxy-5-(hydroxymethyl)-1,3-phenylene]bis(azo)]bisnaphthalene-1-sulphonate
(synonym Brown HT) is widely used as a food color and thus the most
likely route of repeated exposure is expected to be through the oral
route and not the dermal route. Hence this end point was considered for
waiver.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: oral
- Remarks:
- combined repeated dose and carcinogenicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Justification for type of information:
- Data is from a peer reviewed publication
- Qualifier:
- according to guideline
- Guideline:
- other: as mentioned below
- Principles of method if other than guideline:
- Combined repeated dose & carcinogenicity study of Chocolate Brown HT in rats orally.
- GLP compliance:
- not specified
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Specified pathogen-free breeding Colony
- Age at study initiation: No data available
- Weight at study initiation:
Males: 54-80 g
Females: 53-82 g
- Fasting period before study: No data available
- Housing: 4/cage
- Diet (e.g. ad libitum): ground Spratts Laboratory Diet No.1, ad libitum
- Water (e.g. ad libitum): Water, ad libitum
- Acclimation period: No data available
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20± 1°C
- Humidity (%): 50-60%
- Air changes (per hr): No data available
- Photoperiod (hrs dark / hrs light): No data available
IN-LIFE DATES: From: To: No data available - Route of administration:
- oral: feed
- Vehicle:
- other: Ground Spratts Laboratory Diet No.1
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: No data available
DIET PREPARATION
- Rate of preparation of diet (frequency): No data available
- Mixing appropriate amounts with (Type of food): Chocolate Brown HT was incorporated at 0, 500, 2000 or 10000 ppm in diet
- Storage temperature of food: No data available
VEHICLE
- Justification for use and choice of vehicle (if other than water): Spratts Laboratory Diet No.1
- Concentration in vehicle: 0, 25, 100 and 500 mg/Kg/day in the diet
- Amount of vehicle (if gavage): No data available
- Lot/batch no. (if required): No data available
- Purity: No data available - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 2 years
- Frequency of treatment:
- Daily
- Remarks:
- Doses / Concentrations:
0, 25, 100 and 500 mg/Kg/day (0, 500,2000 and 10000 ppm)
Basis:
nominal in diet - No. of animals per sex per dose:
- Total: 384
0 mg/kg/day: 48 male, 48 female
25 mg/kg/day: 48 male, 48 female
100 mg/kg/day: 48 male, 48 female
500 mg/kg/day: 48 male, 48 female - Control animals:
- yes, concurrent vehicle
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily
- Cage side observations checked: Cumulative mortality was observed
DETAILED CLINICAL OBSERVATIONS: No data
- Time schedule:
BODY WEIGHT: Yes
- Time schedule for examinations: On first day of feeding and at 1, 4, 7 and 11 weeks of treatment and thereafter at approx. 3-monthly intervals up to week 102
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes
- Time schedule for examinations: measured over the 48-h period commencing at the same time as the food intake
OPHTHALMOSCOPIC EXAMINATION: No
- Time schedule for examinations:
- Dose groups that were examined:
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At week 14, 27, 55 and 80
- Anaesthetic used for blood collection: Barbiturate anaesthesia was used
- Animals fasted: Overnight
- How many animals: 10 male and 10 female rats and from all the animals at the end of the experiment
- Parameters checked: Haemoglobin content, packed cell volume and counts of erythrocytes and total leucocytes. Reticulocyte and differential white cell counts were carried out in blood samples from control rats and those given 10,000 ppm Chocolate Brown HT in the diet for 14 and 27 weeks only
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: After week 104
- Animals fasted: Overnight
- How many animals: From all the surviving animals
- Parameters checked: Serum was analysed for its content of urea, glucose, total protein and albumin and for the activities of glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase and lactic dehydrogenase
URINALYSIS: Yes
- Time schedule for collection of urine: At weeks 14, 27, 56 and 102
- Metabolism cages used for collection of urine: No data
- Animals fasted: 6-h period of water deprivation and over a 4-h period commencing after 16 h without water
- Parameters checked: Specific gravity and volume of urine, appearance, microscopic constituents and content of cells, glucose, ketones, bile salts and blood were examined.
NEUROBEHAVIOURAL EXAMINATION: No
- Time schedule for examinations:
- Dose groups that were examined: No data
- Battery of functions tested: sensory activity / grip strength / motor activity / other: No data
OTHER:
Organ Weights: Yes
Brain, heart, liver, spleen, kidneys, stomach, small intestine, caecum, adrenals, gonads, pituitary and thyroid were weighed. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
Any macroscopic abnormalities were observed.
Samples of all major tissues and organs and of any other tissue appearing abnormal at autopsy were preserved in 10% buffered formalin until prepared for histological examination.
HISTOPATHOLOGY: Yes
Organ examined: Brain, heart, liver, spleen, kidneys, stomach, small intestine, caecum, adrenals, gonads, pituitary and thyroid were weighted - Other examinations:
- No data available
- Statistics:
- Statistical calculations are based on a level of significance of at least P = 0.05.
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- Cumulative mortality was similar in the treated and control animals throughout the 2-year period except for one statistically significant value at week 72 (7 deaths compared with none in the controls) in males given 500mg/Kg/day
- Mortality:
- no mortality observed
- Description (incidence):
- Cumulative mortality was similar in the treated and control animals throughout the 2-year period except for one statistically significant value at week 72 (7 deaths compared with none in the controls) in males given 500mg/Kg/day
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant decrease was observed in 500 mg/kg/day treated rats as compared to control at 102 week in male and 78 week in female
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- No statistically significant differences between treated and control animals observed.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Description (incidence and severity):
- No statistically significant differences between treated and control animals observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- There were no statistically significant differences between treated and control animals in the terminal haematological studies. Any hematological changes detected were not considered to be treatment related.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- No significant differences between treated and control animals observed
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- No significant differences between treated and control animals observed
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- A slight reduction in testis weight at 25 mg/Kg day observed. The only statistically significant differences were slightly higher relative spleen and kidney weights in males given diet containing 500 mg/Kg day
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- High incidence of adenosis and fibroadenosis in the female rats, but the incidences in the treated and control animals showed no statistical differences.
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- There was a wide range of pathological changes, particularly in the liver and kidney although, with the exception of a lower incidence of fatty change in the livers of males given 100 or 500 mg/kg day of the colouring compared with the controls
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
- Details on results:
- HAEMATOLOGY: When treated with 10000 ppm, in male and female rat significant decrease were observed in hemoglobin at 55 week, WBC at 27 and 55 week in male rat and significant increase in RBC at 27 week in male and female rat as compared to control.
When treated with 2000 ppm, significant increase was observed in RBC of male and female rat and increase in WBC in female as compared to control.
Observed effect was not considered to be treatment related.
ORGAN WEIGHTS: When treated with 10000 ppm, slight increased in relative spleen and kidney weights were observed as compared to control.
When treated with 5000 ppm, slight decrease in testis weight of male rat and slight increase in relative spleen weight were observed in female rat as compared to control.
GROSS PATHOLOGY: The incidence of tumours was low in all groups, the most common tumours being mammary adenomas and fibroadenomas in the female rats, interstitial cell tumours of the testis, and subcutaneous fibromas in both sexes. The incidence of these findings in the treated and control animals did not differ statistically. Very few of the tumours were malignant.
No indication of pigmentation or storage phenomena was observed in any tissues.
HISTOPATHOLOGY: NON-NEOPLASTIC
When treated with 2000 and 10000 ppm, in male rat wide range of pathological changes in liver and kidney with lower incidence of fatty change in the livers were observed as compared to control.
High incidence of adenosis and fibroadenosis in the female rats were observed, but the effect was not statistically significant as compared to control. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 500 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical biochemistry
- food consumption and compound intake
- gross pathology
- haematology
- histopathology: non-neoplastic
- mortality
- organ weights and organ / body weight ratios
- urinalysis
- water consumption and compound intake
- Critical effects observed:
- not specified
- Conclusions:
- The NOAEL for Chocolate Brown HT (Disodium 4,4'-[[2,4-dihydroxy-5-(hydroxymethyl)-1,3-phenylene]bis(azo)]bisnaphthalene-1-sulphonate ) in male/ female Wistar rats was determined to be 500 mg/Kg/day
- Executive summary:
In a Combined repeated dose & carcinogenicity study, the effect of Chocolate Brown HT ( Disodium 4,4'-[[2,4-dihydroxy-5-(hydroxymethyl)-1,3-phenylene]bis(azo)]bisnaphthalene-1-sulphonate) on male and female Wistar rats was studied. The test material was given in the diet for 2 years at a dose level of 0, 25, 100 and 500 mg/Kg/day (0, 500,2000 and 10000 ppm). No effect were observed on overall mortality rate, food consumption, water intake, hematology, clinical chemistry, urine analysis and organ weight of 10000 ppm treated male and female rats as compared to control. In addition, lower incidence of fatty change in the livers in male, adenosis and fibroadenosis in the female and tumours of mammary adenomas and fibroadenomas in the female rats, interstitial cell tumours of the testis and subcutaneous fibromas in both sexes were observed. The observed effects were not related to treatment.
Therefore, the NOAEL for Chocolate Brown HT in male/ female Wistar rats was determined to be 500 mg/Kg/day.
Reference
The overall mortality rate was not affected by treatment with Chocolate Brown HT. The histopathological changes were those expected in ageing rats, and apart from the lower incidence of fatty change seen in the livers of rats given the 2 higher dietary levels of the colouring, their incidence and severity were similar in both test and control rats.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 500 mg/kg bw/day
- Study duration:
- chronic
- Species:
- rat
- Quality of whole database:
- Data is of K2 level from a peer reviewed publication
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: inhalation
- Data waiving:
- exposure considerations
- Justification for data waiving:
- other:
- Critical effects observed:
- not specified
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: dermal
- Data waiving:
- exposure considerations
- Justification for data waiving:
- other:
- Critical effects observed:
- not specified
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Repeated
dose toxicity: oral
No.
of studies of Chocolate Brown HT were reviewed for repeated dose
toxicity by oral route from reliable sources having Klimisch rating 2.
The summary of the results is presented below:
For key study a Combined repeated dose & carcinogenicity study was carried in which the effect of Chocolate Brown HT ( Disodium 4,4'-[[2,4-dihydroxy-5-(hydroxymethyl)-1,3-phenylene]bis(azo)]bisnaphthalene-1-sulphonate) on male and female Wistar rats was studied. The test material was given in the diet for 2 years at a dose level of 0, 25, 100 and 500 mg/Kg/day (0, 500,2000 and 10000 ppm). No effect were observed on overall mortality rate, food consumption, water intake, hematology, clinical chemistry, urine analysis and organ weight of 10000 ppm treated male and female rats as compared to control. In addition, lower incidence of fatty change in the livers in male, adenosis and fibroadenosis in the female and tumours of mammary adenomas and fibroadenomas in the female rats, interstitial cell tumours of the testis and subcutaneous fibromas in both sexes were observed. The observed effects were not related to treatment. Therefore, the NOAEL for Chocolate Brown HT in male/ female Wistar rats was determined to be 500 mg/Kg/day.
Further, In a Chronic repeated dose toxicity study, Porton SPF Wistar male and female rat were treated with Chocolate Brown HT ( Disodium 4,4'-[[2,4-dihydroxy-5-(hydroxymethyl)-1,3-phenylene]bis(azo)]bisnaphthalene-1-sulphonate) in the concentration of 0.0, 0.5, 1.0 and 2.0% (equivalent to 0, 500, 2000 and 1000 mg/Kg/day) in diet. No effect on survival was observed. Growth retardation, significant decrease body weight and mild degree of renal dysfunction were observed in 1.0 and 2.0 % treated rats. Significant increase were observed in relative brain, adrenals, right and left kidney, spleen and gonads weight of male and female rat as compared to control. In addition, histopathological changes such as brown pigmentation in the Kupffer cells of the liver, the proximal convoluted tubules of the kidney and the lymph nodes especially of the small intestine were observed. The intensity of observed effect was proportional to the dietary level administered and the pigment was only very occasionally present. A no-effect level (NOEL) is therefore established of 500 mg/Kg/day of Chocolate Brown HT in the diet of rats for 12 wk.
Similarly, In a Chronic repeated dose toxicity study, Weanling Carforth Farm male and female rat were treated with Chocolate Brown HT (Disodium 4,4'-[[2,4-dihydroxy-5-(hydroxymethyl)-1,3-phenylene]bis(azo)]bisnaphthalene-1-sulphonate) in the concentration of 0.0, 0.02, 0.2, 0.60, 1.0 and 2.0 % orally. No effect on survival, clinical sign and body weight and body weight gain was observed in treated rats. Increased food consumption and reduced food efficiency were observed in 1.0 and 2.0 % dose group rats. Significant decreased in hemoglobin, red cell count and packed cell volume were observed in 2.0 % treated male rats and changes in Total serum protein and blood urea concentration level of 1.0 and 2.0 % male and female rats. In addition, darker colour of the viscera was observed in 2.0 % treated rats. Therefore, NOEL was considered to be 0.60 % (300 mg/kg/day) when Weanling Carforth Farm male and female rat were treated with Chocolate Brown HT orally for 90 days.
In addition to above similar type of Chronic repeated dose toxicity study was carried out where Tuck TF1 male and female mice treated with Chocolate Brown HT (Disodium 4,4'-[[2,4-dihydroxy-5-(hydroxymethyl)-1,3-phenylene]bis(azo)]bisnaphthalene-1-sulphonate) in the concentration of 0.00, 0.01, 0.1 and 0.5 % (0, 14.3, 140 and 700 mg/kg/day ) orally. No effect was observed on survival, body weight, organ weight and histopathology of treated rat. In addition, increases in Red Blood Cells and decreased in Packed cell volume and Total Leucocytes count of 0.1 and 0.5 % treated mice were observed. Brown colouration of lymph nodes, intestine, ovaries and uterus was observed occasionally at 0.5 % treated mice as compared to control. Therefore, NOAEL was considered to be > 0.1 % (> 140 mg/Kg/day) when Tuck TF1 male and female mice were treated with Chocolate Brown HT orally for 80 weeks.
Further supporting above studies, yet another chronic toxicity study was carried out where Large White pigs were treated with Chocolate Brown HT (Disodium 4,4'-[[2,4-dihydroxy-5-(hydroxymethyl)-1,3-phenylene]bis(azo)]bisnaphthalene-1-sulphonate). The test substance was given in the diet to groups of 3 male and 3 female pigs at dose levels of 0 (control), 5, 20 or 100 mg/kg/day for 13 weeks. On the basis of various observations made, faeces from both male and female pigs on the highest treatment level (100 mg/kg) were very dark brown and occasionally maroon in colour. The dark colour of the faeces indicated either that a proportion of the colour remained unabosrbed or that a coloured metabolite was similarly unabsorbed. The observations of a maroon colour suggest that it was a metabolite that was present. The haemoglobin concentrations were significantly less than the control values in the male pigs but not related to the administration of colours. The present study showed that the daily ingestion of up to 100 mg of Chocolate Brown HT/kg for up to 90 days in pigs produced no detectable adverse effects. Therefore, NOAEL was considered to be 100 mg/kg/day in Large White pigs treated with Chocolate Brown HT orally for 13 weeks.
Based on the studies summarized above it can be observed that NOAEL value varies from 100 to 500 mg/Kg bw/ day. The main effects observed on these doses were as follows:
· No adverse effect on survival, body weight, food consumption and efficiency, ophthalmoscopy, haematology, clinical chemistry, urinalysis, organ weight, gross pathology and histopathology
· No adverse effect on clinical sign and body weight.
Since no effective dose value (NOAEL) is 500 mg/Kg bw/d thus based on this value it can be concluded that substance CAS NO 4553-89-3 is considered to be not toxic to repeated dose via oral route for the above mentioned dose.
Repeated
dose toxicity: inhalation
In
accordance with column 2 of Annex VIII of the REACH regulation, testing
by the inhalation route is appropriate if exposure of humans via
inhalation is likely taking into account the vapour pressure of the
substance. This chemical ha a very low vapour pressure of 1.48E-33
Pascal at 25°C and thus exposure by the inhlation route for this
chemical is unlikely.
Repeated
dose toxicity: dermal
The
chemical disodium
4,4'-[[2,4-dihydroxy-5-(hydroxymethyl)-1,3-phenylene]bis(azo)]bisnaphthalene-1-sulphonate
(synonym Brown HT) is widely used as a food color and thus the most
likely route of repeated exposure is expected to be through the oral
route and not the dermal route. Hence this end point was considered for
waiver.
Justification for classification or non-classification
The available studies from reliable sources indicate that the test substance is not likely to be toxic by repeaded exposure by the oral route.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.